Absci (ABSI) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Palvella Therapeutics (PVLA) over the past year, gaining 153.4% versus a gain of 98.0%. Over five years, ABSI leads with a -4.4% price change compared with -61.5% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.00 billion vs $1.74 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | PVLA |
|---|---|---|
| Share price | $10.16 | $138.77 |
| Market cap | $1.74B | $2.00B |
| 1-day change | +13.65% | +5.66% |
| YTD return | +191.12% | +32.58% |
| 1-year return | +153.37% | +97.99% |
| 5-year return | -4.42% | -61.54% |
| EPS (TTM) | $-0.79 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | $-41.72M |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $161.38 |
| 52-week low | $2.24 | $66.58 |
| Distance from 52-week high | -15.72% | -14.01% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +41.73% | +66.12% |
| Average volume | 3.43M | 211.30K |
| Shares outstanding | 171.61M | 14.41M |
| Employees | 140 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed PVLA by 55.4 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Healthcare · Biotechnology · 140 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Healthcare · Biotechnology · 29 employees
ABSI vs PVLA FAQ
Which is bigger, Absci or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.00B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or PVLA?
ABSI returned +153.37% over the past 12 months, compared with +97.99% for PVLA (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.